Core Viewpoint - Mei Rui Health International (02327) expects to achieve a profit attributable to shareholders between approximately HKD 14 million and HKD 16 million for the six months ending June 30, 2025, compared to approximately HKD 8.2 million for the six months ending June 30, 2024 [1] Group 1: Profit Expectations - The anticipated increase in profit is primarily due to growth in property-related business revenue and profit, driven by increased rental income and stable fair value of investment properties for the six months ending June 30, 2025 [1] - In contrast, the fair value of investment properties experienced a significant decline for the six months ending June 30, 2024 [1] Group 2: Interest Income - The company benefited from effectively utilizing idle funds to provide short-term interest-bearing loans and long-term revolving financing to clients and related parties, resulting in increased interest income [1] Group 3: Adverse Factors - These positive factors were partially offset by a challenging domestic operating environment, leading to a decrease in trade sales and revenue from health and medical-related products [1]

Core Viewpoint - Meirui Health International (02327.HK) expects a significant increase in shareholder profit for the six months ending June 30, 2025, projecting between approximately HKD 14 million to HKD 16 million, compared to approximately HKD 8.2 million for the six months ending June 30, 2024 [1] Group 1: Profit Expectations - The anticipated increase in profit is primarily due to growth in property-related business revenue and profit, driven by increased rental income and stable fair value of investment properties [1] - The fair value of investment properties experienced a significant decline for the six months ending June 30, 2024, contrasting with the stability expected for the upcoming period [1] Group 2: Revenue Sources - The company has benefited from utilizing idle funds to provide short-term interest-bearing loans and long-term revolving financing to clients and related parties, resulting in increased interest income [1] - However, this positive impact is partially offset by a challenging domestic operating environment, leading to a decrease in trade sales and revenue from health and medical-related products [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 MEILLEURE HEALTH INTERNATIONAL INDUSTRY GROUP LIMITED 美 瑞 健 康 國 際 產 業 集 團 有 限 公 司 本公司董事（「董事」）會（「董事會」）謹此知會本公司股東（「股東」）及本公司潛在投 資者，基於初步評估本集團截至二零二五年六月三十日止六個月之未經審核綜合管理賬目及本 公司目前可得資料，本集團預期於截至二零二五年六月三十日止六個月錄得股東應佔溢利介乎 約14.0百萬港元至16.0百萬港元，而截至二零二四年六月三十日止六個月則錄得股東應佔溢利 為約8.2百萬港元。有關預期增加的主要原因如下： 而上述因素被以下不利因素部分抵銷： (iii) 國內經營環境依然困難，故貿易銷售額及健康醫療相關產品的收入有所減少。 本公告所載資料僅以董事會根據本集團截至二零二五年六月三十日止六個月未經審核綜合管理 賬目所作之初步評估及董事會於本公告日期可得之資料為基準， ...

格隆汇8月14日丨美瑞健康国际(02327.HK)宣布，本公司的董事会会议将于2025年8月28日（星期四）举 行，以批准（其中包括）本公司及其附属公司截至2025年6月30日止六个月期间的中期业绩及考虑派付 中期股息（如有）。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴 該等內容而引致之任何損失承擔任何責任。 MEILLEURE HEALTH INTERNATIONAL INDUSTRY GROUP LIMITED 美 瑞 健 康 國 際 產 業 集 團 有 限 公 司 （於百慕達註冊成立之有限公司） （股份代號：2327） 董事會會議日期 美瑞健康國際產業集團有限公司(「本公司」)董事會(「董事會」)宣佈，本公司之董事會 會議將於二零二五年八月二十八日（星期四）舉行，以批准（其中包括）本公司及其附屬 公司截至二零二五年六月三十日止六個月期間的中期業績及考慮派付中期股息（如有）。 承董事會命 美瑞健康國際產業集團有限公司 執行董事及行政總裁 周文川 香港，二零二五年八月十四日 於本公告日期，董事會包括執行董事周旭洲先生、曾文濤博士及周文川女士，非執行董事毛振 華博士，及獨立非執行董事周志偉教授、陳實先生及吳鵬先生。 — 1 — ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 美瑞健康國際產業集團有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02327 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | ...

Market Growth and Demand - The health industry in China is projected to reach a market size of over RMB 16 trillion by 2030, indicating significant growth potential[9]. - By the end of 2024, the population aged 60 and above in China is expected to exceed 290 million, creating substantial demand in the health sector[10]. - The "silver economy" market size has surpassed RMB 9 trillion, driven by the aging population and increasing health needs[10]. - The demand for preventive medicine and personalized health management is rapidly increasing among younger demographics, leading to growth in niche markets like nutritional health and genetic testing[10]. - The Chinese stem cell market is projected to reach approximately RMB 26.5 billion by 2024, indicating strong growth potential[14]. Company Strategy and Focus - The company is focusing on cell therapy and health management, leveraging its extensive experience in skin health management to optimize product offerings[12]. - The company aims to enhance its investment strategies and capitalize on emerging opportunities in the health sector amidst a challenging economic environment[12]. - The company is committed to long-term growth, emphasizing the importance of maintaining a solid operational foundation while exploring new business avenues[12]. - The company is actively seeking new opportunities and breakthroughs in the health industry, aligning with national health policies and market trends[12]. - The company is focused on exploring commercialization pathways for cell therapy products and enhancing synergies between health management and other business segments[18]. - The company aims to deepen its layout in cell therapy research and applications, responding to increasing market demand for related products[18]. Financial Performance - The company's revenue for the year ended December 31, 2024, was approximately HKD 50.7 million, a decrease of about 60.8% from HKD 129.3 million in 2023[28]. - Gross profit for the year ended December 31, 2024, was approximately HKD 28.9 million, down about 63.0% from HKD 78.1 million in 2023, with a gross margin of 57.0% compared to 60.4% in the previous year[29]. - Other income and net gains for the year ended December 31, 2024, increased to approximately HKD 53.3 million, a rise of about 114.1% from HKD 24.9 million in 2023[31]. - Total operating expenses for the year ended December 31, 2024, were approximately HKD 31.6 million, a decrease of about 19.6% from HKD 39.3 million in 2023[32]. - Profit after tax for the year ended December 31, 2024, was approximately HKD 32.0 million, down about 16.9% from HKD 38.5 million in 2023[34]. Assets and Liabilities - Non-current assets as of December 31, 2024, were approximately HKD 980.4 million, an increase of about 26.0% from HKD 778.4 million in 2023[43]. - Current assets as of December 31, 2024, were approximately HKD 688.3 million, a decrease of about 25.1% from HKD 918.8 million in 2023[43]. - The group’s net asset value as of December 31, 2024, was approximately HKD 1,201.4 million, down from HKD 1,254.3 million in 2023[42]. - The group’s total liabilities as of December 31, 2024, were approximately HKD 467.3 million, an increase from HKD 442.9 million in 2023[42]. Investment and Financing - The group remains committed to investing in the health industry, aiming to capture market opportunities in this sector[59]. - The group has established strict credit risk management and internal control procedures for its lending transactions[62]. - The group has a structured procedure for handling overdue payments, including reminders and collection actions[64]. - The group plans to explore cross-selling opportunities with Yincuan Bio, aiming for synergistic effects[112]. Corporate Governance - The company has adopted the Corporate Governance Code and has complied with all applicable code provisions during the year ending December 31, 2024[176]. - The board has established four committees: Audit Committee, Remuneration Committee, Nomination Committee, and Strategic Committee to oversee various aspects of the group's operations[183]. - The independent non-executive directors have a one-year appointment term or until they retire according to company bylaws[189]. - The board has implemented a mechanism to ensure strong independence and efficiency in decision-making, which is reviewed annually[187]. Employee and Management - As of December 31, 2024, the group had approximately 46 employees, a decrease from 57 employees in 2023, with employee costs amounting to approximately HKD 13.7 million, down from HKD 14.1 million in 2023[76]. - The group has adopted a share option scheme in 2019 to attract and retain skilled employees[77]. - The Compensation Committee ensures that no director or their associates participate in determining their own remuneration[197]. Related Party Transactions - The company has entered into a financing agreement with Guangyu Zhaoneng, providing a revolving loan of up to RMB 200,000,000 at an interest rate of the one-year loan market quotation rate plus 3.05%[142]. - Guangyu Zhaoneng is controlled by a director of the company, making it a related party transaction[142]. - Independent non-executive directors have confirmed that the related transactions are conducted in the ordinary course of business and on normal commercial terms[151].

Financial Performance - Total revenue for the year ending December 31, 2024, was HKD 50,676,000, a decrease of 60.8% compared to HKD 129,304,000 for the year ending December 31, 2023[3]. - Gross profit for the year was HKD 28,905,000, down 63.0% from HKD 78,090,000 in the previous year[3]. - Net profit for the year was HKD 32,045,000, a decline of 16.8% compared to HKD 38,490,000 in the prior year[3]. - Basic and diluted earnings per share were HKD 0.79, down from HKD 1.00 in the previous year[3]. - The total comprehensive income for the year ended December 31, 2024, was HKD 32,045,000, compared to HKD 38,490,000 in the previous year, representing a decrease of approximately 16%[4]. - The company reported a total comprehensive loss of HKD 37,747,000 for the year, compared to a loss of HKD 7,604,000 in the previous year, indicating a significant increase in losses[4]. - The company reported interest income of HKD 22,045,000, an increase from HKD 18,824,000 in the previous year, reflecting a growth of about 17.5%[13]. - Profit after tax for the year ended December 31, 2024, was approximately HKD 32.0 million, a decrease of about HKD 6.5 million or approximately 16.9% from HKD 38.5 million for the year ended December 31, 2023[66]. Revenue Breakdown - Revenue from the healthcare-related business for the year ended December 31, 2024, was approximately HKD 19.6 million, a decrease of about HKD 28.5 million or approximately 59.3% compared to HKD 48.1 million for the year ended December 31, 2023[68]. - Revenue from the trading business for the year ended December 31, 2024, was approximately HKD 13.8 million, a decrease of about HKD 48.8 million or approximately 78.0% from HKD 62.6 million for the year ended December 31, 2023[69]. - Revenue from property-related business for the year ended December 31, 2024, was approximately HKD 17.2 million, a decrease of about HKD 1.4 million or approximately 7.5% compared to HKD 18.6 million for the year ended December 31, 2023[70]. - Revenue from health-related products sales reached HKD 37,791,000 in 2024, up from HKD 7,516,000 in 2023, marking a growth of 402%[21]. - Income from new energy product procurement services surged to HKD 20,841,000 in 2024, compared to HKD 1,006,000 in 2023, reflecting a growth of 1985%[21]. Expenses and Liabilities - Administrative expenses were HKD 24,615,000, slightly up from HKD 24,474,000 year-over-year[3]. - The company recognized an impairment loss of HKD 20,224,000, compared to HKD 3,962,000 in the previous year, indicating a significant increase in asset impairment[3]. - The total liabilities for the company were HKD 158,342,000, down from HKD 223,994,000 in the previous year, indicating a reduction of approximately 29%[5]. - The total liabilities included bank loans of HKD 218,645,000, which increased from HKD 137,315,000, indicating a rise of approximately 59.3%[6]. - The group reported a significant decrease in gross profit, mainly due to reduced sales in healthcare-related products and trading business, which contributed to a drop of approximately HKD 49.2 million in gross profit[61]. Assets and Equity - The company's non-current assets amounted to HKD 980,356,000 as of December 31, 2024, an increase from HKD 778,429,000 in the previous year, reflecting a growth of about 26%[5]. - The company's total assets, net of current liabilities, stood at HKD 1,510,309,000, compared to HKD 1,473,215,000 in the previous year, showing an increase of approximately 3%[5]. - The company's total equity attributable to shareholders decreased to HKD 37,341,000 from HKD 5,261,000, indicating a substantial decline in shareholder equity[4]. - The net asset value of the company was HKD 1,201,364,000, down from HKD 1,254,321,000, indicating a reduction of approximately 4.2%[6]. Strategic Focus and Future Plans - The company plans to focus on new product development and market expansion strategies to improve future performance[2]. - The company plans to expand its market presence and enhance its product offerings in the health and new energy sectors[21]. - Future guidance indicates a continued focus on increasing revenue streams from health management services and new energy products[21]. - The company aims to optimize its skincare products and business models based on years of experience in skin health management[42]. - The company is committed to research and development to improve its product efficacy and expand its service offerings[121]. Market Trends and Opportunities - The health industry is projected to reach a market size of over RMB 16 trillion by 2030, indicating significant growth potential[40]. - By the end of 2024, the population aged 60 and above in China is expected to exceed 290 million, creating substantial downstream demand for health services[41]. - The "silver economy" market size has surpassed RMB 9 trillion, driven by the aging population[41]. - The company is exploring opportunities for market expansion in both domestic and international markets[126]. Corporate Governance and Compliance - The board believes that good corporate governance is essential for effective management and has adhered to the corporate governance code during the financial year[113]. - The audit committee has reviewed the consolidated financial statements for the year ended December 31, 2024, including the accounting principles adopted[115]. - The company has established strict credit risk management and internal control procedures for its lending activities[93]. Employee and Shareholder Relations - The company expressed gratitude to its employees for their contributions and to shareholders for their trust and support[123]. - The company is committed to providing training for new employees to familiarize them with the work environment and culture[107]. - The proposed final dividend is HKD 0.4 per share for the year ended December 31, 2024, consistent with the previous year[109].

美 瑞 健 康 国 际 产 业 集 团 Meilleure Health International Industry Group 中期報告 ２０２４ Meilleure Health International Industry Group Limited 美瑞健康國際產業集團有限公司 (於百慕達註冊成立之有限公司) (股份代號：2327) 目錄 2 公司資料 3 管理層討論及分析 2 20 其他資料 3 32 董事及高級管理人員履歷 20 36 中期簡明綜合損益表 32 37 中期簡明綜合全面收益表 36 38 中期簡明綜合財務狀況表 37 40 中期簡明綜合權益變動表 38 41 中期簡明綜合現金流量表 40 42 中期簡明綜合財務報表附註 41 66 詞彙 42 66 詞彙 中期報告2024 ／ 美瑞健康國際產業集團有限公司 公司資料 | --- | --- | |-------------------------------------------------------------------------|--------------------------------------------| ...

Financial Performance - Revenue for the six months ended June 30, 2024, was HKD 30,033,000, a decrease of 59.93% compared to HKD 74,838,000 for the same period in 2023[2] - Gross profit for the same period was HKD 15,393,000, down 58.40% from HKD 36,949,000 year-over-year[2] - Net profit for the six months ended June 30, 2024, was HKD 8,230,000, a decline of 53.55% compared to HKD 17,732,000 in the previous year[3] - Basic earnings per share for the period was HKD 0.21, down from HKD 0.44 in the same period last year[2] - The company reported a net profit attributable to shareholders of HKD 8,465 million, down from HKD 18,160 million in the prior year[31] - The profit after tax for the six months ended June 30, 2024, was approximately HKD 8.2 million, a decrease of about 53.7% from HKD 17.7 million for the same period in 2023[37] Assets and Liabilities - Total non-current assets as of June 30, 2024, amounted to HKD 964,843,000, an increase from HKD 778,429,000 as of December 31, 2023[4] - Current assets totaled HKD 700,087,000, a decrease from HKD 918,780,000 at the end of the previous year[4] - The company's total assets decreased to HKD 1,428,876 thousand from HKD 1,473,215 thousand, indicating a reduction in asset base[6] - Total current liabilities increased to HKD 236,054 thousand from HKD 223,994 thousand year-over-year, with bank loans slightly rising to HKD 161,288 thousand[6] - Non-current liabilities decreased to HKD 209,438 thousand from HKD 218,894 thousand, primarily due to a reduction in bank loans[6] - The company’s equity attributable to owners decreased to HKD 1,219,486 thousand from HKD 1,254,155 thousand, reflecting a decline in retained earnings[6] Cash Flow - The company reported a net cash inflow from operating activities of HKD 109,286 thousand for the six months ended June 30, 2024, compared to a net cash outflow of HKD 83,276 thousand in the same period last year[8] - Cash and cash equivalents at the end of the period were HKD 6,643 thousand, down from HKD 65,243 thousand at the end of the previous period[8] - The company reported a significant cash outflow from investing activities amounting to HKD 201,295 thousand, compared to HKD 44,969 thousand in the previous period[8] Segment Performance - Total revenue for the six months ended June 30, 2024, was HKD 30,033 million, with a significant contribution from healthcare-related businesses at HKD 11,480 million[14] - The segment profit for healthcare-related businesses was HKD 1,100 million, while the trading business reported a profit of HKD 6,594 million[14] - Revenue from healthcare management services increased to HKD 1,933 million, up from HKD 1,226 million in the same period last year[17] - Revenue from sales of construction materials was HKD 8,718 million, a decrease from HKD 33,087 million year-over-year[17] - The trading business segment's revenue was HKD 10,327 million, contributing to the overall revenue growth[14] Investment and Financing - The company has established a financing agreement with Guangyu Zhaoneng for providing circular loan financing, effective from November 27, 2023[88] - The company reported a maximum unsecured revolving loan facility of RMB 200 million from Guangyu Zhaoneng[89] - The total outstanding loans receivable amounted to HKD 408,272,000, with a breakdown showing that HKD 214,880,000 (52.6%) is due from Guangyu Zhaoneng[60] Corporate Governance and Compliance - The company has adopted and complied with all applicable corporate governance principles as of June 30, 2024[81] - The company has adopted the standards set forth in the Listing Rules Appendix C3 regarding directors' securities trading, confirming compliance as of June 30, 2024[82] - The Audit Committee has reviewed the accounting principles and practices adopted by the group, discussing internal controls and financial reporting matters[84] Market and Business Strategy - The company is engaged in health care, building materials, new energy products trading, and real estate services, indicating a diversified business model[9] - The company plans to expand its market presence and invest in new technologies to enhance its service offerings[18] - The company aims to strengthen its international strategy and expand its overseas business, enhancing brand depth and market reach[77] Research and Development - The company has made significant progress in the field of cell therapy, with 4 cell drug clinical trial applications accepted by the National Medical Products Administration, including 2 that received implied approval for clinical trials[71] - The company has filed multiple patents related to cell therapy technologies, indicating its commitment to innovation in this field[71] - The company is exploring commercialization pathways for cell therapy products, aiming for synergistic development between health management and other business segments[72] Employee and Operational Metrics - The total number of employees decreased to 52 as of June 30, 2024, from 57 as of December 31, 2023[66] - The company’s clinics in Shenzhen and Nanjing are providing high-end health management services based on functional medicine, attracting a loyal customer base[72]